jRCT2080221095未知1 期
A Phase I, Open-Label Study to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Doses of MEDI-575 in Patients With Advanced Solid Malignancies
试验速览
- 阶段
- 1 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •Having advanced solid malignancy for which no curative or standard therapies exist
- •Karnofsky performance status of 60 or more
- •Patients must have histological confirmed diagnosis of HCC with no standard therapy available (for only expansion part)
排除标准
- •Inadequate bone marrow reserve or organ function
- •Major surgery within 4 weeks or minor surgery within 2 weeks prior to receipt of MEDI-
- •Patients must have no unhealed wounds or unhealed fractures
- •History of allergy or reaction to any component of the MEDI-575 and/or monoclonal antibody
研究者
相似试验
未知
1 期
A Phase I, Open-Label Study to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Doses of MEDI-575 in Patients With Advanced Solid MalignanciesJPRN-jRCT2080221095AstraZeneca
已完成
1 期
A Phase 1, Open-Label Study Evaluating the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of SM07883, a Novel DYRK1a Inhibitor, Following Oral Administration to Healthy SubjectsNeurological - Alzheimer's diseaseAlzheimer's DiseaseACTRN12619000327189Samumed Pacific Pty Ltd28
已完成
1 期
A clinical study to assess the safety, tolerability & immunogenicity of Measles Rubella(MR) vaccine in 4 to 5 years old healthy children.CTRI/2022/03/040874Biological E Limited24
已完成
1 期
A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of MEDI9447 (Oleclumab) in Japanese Patients with Advanced Solid MalignanciesjRCT2080224133AstraZeneca12
已完成
1 期
A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of MEDI9447 (Oleclumab) in Japanese Patients with Advanced Solid MalignanciesAdvanced Solid MalignanciesJPRN-jRCT2080224133AstraZeneca12